Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
October 2013

Levomilnacipran (Fetzima): One More SNRI
Levomilnacipran (Fetzima), the newest serotonin-norepinephrine reuptake inhibitor (SNRI), appears superior to placebo in reducing depression symptoms.

Quetiapine in Adolescents with Schizophrenia
In one study, a lower dose (400 mg/day) of quetiapine (Seroquel and others) was as efficacious as a higher dose (800 mg/day) for treating schizophrenia in adolescents.

SSRIs and the Metabolic Syndrome
Some selective serotonin reuptake inhibitor (SSRI) antidepressants appear to increase the risk of the metabolic syndrome, while others do not.

In Brief
ACE Inhibitors May Slow Rate of Cognitive Decline in Patients with Dementia; Risk of Bipolar Disorder and Schizophrenia Is Higher in Relatives of Patients with ADHD

After ECT
Patients who respond to treatment with electroconvulsive therapy (ECT) should receive vigorous maintenance therapy, but there is as yet no expert consensus as to what that therapy should be.

In Brief

October 2013

Although no agents have been identified that prevent or reverse dementia, there is evidence that some antihypertensive agents may lower the risk of developing it (Gao et al. BMJ Open 2013 Jul 25;3(7). doi: 10.1136/bmjopen-2013-002881). Gao and colleagues studied the effects of treatment with…

To view the rest of this article, please: